Catalyst
Monitor for regulatory updates and further data presentations from the BRUIN CLL-322 trial.
Date
June 15, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.